Pioneering Pharmaceuticals rose nearly 35% at one point, and the third phase of the new crown oral drug completed the first drug administration in China

On February 14, Hong Kong stocks pioneered the pharmaceutical industry (09939. HK) rose nearly 35% at one point and nearly 25% as of press time, with a market capitalization of more than HK$4.7 billion.

On the news side, on February 11, Pioneering Pharmaceutical issued an announcement that the global multi-center phase III clinical trial (NCT04869228) for the treatment of mild and moderate covid-19 patients with puklum has completed the enrollment and administration of the first subject in China at the Third People's Hospital of Shenzhen.

Pkrutamine belongs to the new generation of androgen receptor (AR) antagonists, originally used to treat prostate cancer and advanced breast cancer Class 1.1 innovative drugs, pioneering pharmaceutical development and exploration in the treatment of new crown pneumonia, is an oral drug to treat new crown.

Pioneer Pharmaceuticals introduced in the announcement that the phase III clinical trial of pkrutamine is a randomized, double-blind, placebo-controlled, global multicenter study aimed at exploring the efficacy and safety of pkrutamine in the treatment of men with mild and moderate COVID-19.

Nearly 200 participants have been enrolled in the trial in countries such as Brazil, the Philippines and Malaysia. China is one of the main participants in this Phase III clinical trial, which was approved by the State Drug Administration on September 1, 2021. At present, the centers participating in the clinical research in China include Beijing Ditan Hospital, China-Japan Friendship Hospital, Shenzhen Third People's Hospital, Shanghai Public Health Clinical Center, Hangzhou Xixi Hospital, Chengdu Public Health Clinical Center and Suzhou Fifth People's Hospital.

The announcement also mentioned that the clinical trial of pkrutamine for severely hospitalized COVID-19 patients (NCT05009732) has fully launched patient enrollment in the United States, Ukraine and the Philippines, and is currently screening patients before enrollment in China Clinical Centers. The relevant work of other countries involved in global multi-center clinical trials is also being actively promoted.

It is worth mentioning that on December 27, 2021, Pioneering Pharmaceutical announced the progress of the phase III clinical trial of pkrutamine for non-hospitalized patients with mild and moderate illness, saying that according to the interim analysis data of 348 cases of new crown patients, due to the small number of events that did not reach statistical significance, the company plans to adjust the clinical trial protocol for patient recruitment. The news led to a 70% plunge in the share price of Pioneering Pharmaceuticals.